Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Evaluation of the prognostic value of pSMAD immunohistochemistry in colorectal cancer.

Voorneveld PW, Jacobs RJ, De Miranda NF, Morreau H, van Noesel CJ, Offerhaus GJ, Kodach LL, Hardwick JC.

Eur J Cancer Prev. 2013 Sep;22(5):420-4. doi: 10.1097/CEJ.0b013e32835e88e2.

PMID:
23426176
2.

Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer.

Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG.

Tumour Biol. 2012 Aug;33(4):1005-14. doi: 10.1007/s13277-012-0333-3. Epub 2012 Jan 26.

PMID:
22278155
3.

The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer.

Kodach LL, Bleuming SA, Musler AR, Peppelenbosch MP, Hommes DW, van den Brink GR, van Noesel CJ, Offerhaus GJ, Hardwick JC.

Cancer. 2008 Jan 15;112(2):300-6.

4.

The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers.

Kodach LL, Wiercinska E, de Miranda NF, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJ, Morreau H, Hommes DW, Ten Dijke P, Offerhaus GJ, Hardwick JC.

Gastroenterology. 2008 May;134(5):1332-41. doi: 10.1053/j.gastro.2008.02.059. Epub 2008 Mar 4.

PMID:
18471510
5.

Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.

Itatani Y, Kawada K, Fujishita T, Kakizaki F, Hirai H, Matsumoto T, Iwamoto M, Inamoto S, Hatano E, Hasegawa S, Maekawa T, Uemoto S, Sakai Y, Taketo MM.

Gastroenterology. 2013 Nov;145(5):1064-1075.e11. doi: 10.1053/j.gastro.2013.07.033. Epub 2013 Jul 25.

PMID:
23891973
6.

Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis.

Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M.

Cancer J. 2003 Jul-Aug;9(4):302-12.

PMID:
12967141
7.

SMAD4/DPC4 expression and prognosis in human colorectal cancer.

Isaksson-Mettävainio M, Palmqvist R, Forssell J, Stenling R, Oberg A.

Anticancer Res. 2006 Jan-Feb;26(1B):507-10.

8.

Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma.

Xie W, Aisner S, Baredes S, Sreepada G, Shah R, Reiss M.

Head Neck. 2013 Jan;35(1):76-85. doi: 10.1002/hed.22924. Epub 2012 Jan 24.

PMID:
22275186
9.

Nuclear expression of Smad proteins and its prognostic significance in clear cell renal cell carcinoma.

Park JH, Lee C, Suh JH, Chae JY, Moon KC.

Hum Pathol. 2013 Oct;44(10):2047-54. doi: 10.1016/j.humpath.2013.03.009. Epub 2013 May 10.

PMID:
23668999
10.

Visualizing TGF-β and BMP signaling in human atherosclerosis: a histological evaluation based on Smad activation.

van Dijk RA, Engels CC, Schaapherder AF, Mulder-Stapel A, Ten Dijke P, Hamming JF, Lindeman JH.

Histol Histopathol. 2012 Mar;27(3):387-96.

PMID:
22237716
11.

SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.

Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM.

Cancer Res. 2013 Jan 15;73(2):725-35. doi: 10.1158/0008-5472.CAN-12-2706. Epub 2012 Nov 8.

12.

Tumoral epithelial and stromal expression of SMAD proteins in pancreatic ductal adenocarcinomas.

Handra-Luca A, Hammel P, Sauvanet A, Ruszniewski P, Couvelard A.

J Hepatobiliary Pancreat Sci. 2013 Mar;20(3):294-302. doi: 10.1007/s00534-012-0518-6.

PMID:
22581056
13.

SMAD4 as a prognostic marker in colorectal cancer.

Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Hemminki A, Schwartz S Jr, Aaltonen LA, Arango D.

Clin Cancer Res. 2005 Apr 1;11(7):2606-11.

14.
15.

Expression of Smad4 and TGF-beta2 in colorectal carcinoma.

Kouvidou Ch, Latoufis C, Lianou E, Kouvatseas G, Kakouri E, Anagnostakis D, Vrettou-Aravani V, Betsi E, Karatapanis S.

Anticancer Res. 2006 Jul-Aug;26(4B):2901-7.

16.

Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study.

Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M.

Cancer Res. 2002 Jan 15;62(2):497-505.

17.

Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis.

Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano L, Jass JR.

Histopathology. 2007 Mar;50(4):453-64.

PMID:
17448021
18.

Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.

Rosendahl A, Speletas M, Leandersson K, Ivars F, Sideras P.

Int Immunol. 2003 Dec;15(12):1401-14.

19.

Monocrotaline pyrrole induces Smad nuclear accumulation and altered signaling expression in human pulmonary arterial endothelial cells.

Ramos M, Lamé MW, Segall HJ, Wilson DW.

Vascul Pharmacol. 2007 Jun;46(6):439-48. Epub 2007 Feb 2.

20.

Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma.

Jain S, Singhal S, Francis F, Hajdu C, Wang JH, Suriawinata A, Wang YQ, Zhang M, Weinshel EH, Francois F, Pei ZH, Lee P, Xu RL.

World J Gastroenterol. 2011 Sep 21;17(35):3994-4000. doi: 10.3748/wjg.v17.i35.3994.

Items per page

Supplemental Content

Write to the Help Desk